Global Laboratory Landscape Data and Strategy for Targeted Therapy Launches: Understanding CDx Intelligence and Trends - Diaceutics
+

Global Laboratory Landscape Data and Strategy for Targeted Therapy Launches: Understanding CDx Intelligence and Trends



Ryan Keeling
Jordan Clark


Will you be launching a targeted therapy in the next 24 to 48 months? This Labceutics webinar provides key insights into laboratory strategy, data and key market landscape differences when planning for a targeted therapy launch.

Join an expert panel of targeted therapy and laboratory data experts to hear about the ‘forgotten’ but critical stakeholder in successful global targeted therapy launches – the molecular laboratory.

Listen to this webinar to learn:

  • How the laboratory landscape and testing environment impacts therapy launches globally
  • Laboratory Mapping and optimal lab footprints based on a therapy, a test and target prescribers
  • The types of biomarker testing being done on a regional basis
  • Key testing measurement criteria about laboratories you need to know
  • Challenges and opportunities in developing regional lab networks to support quality testing

Expert Insights

The CMS National Coverage Decision on NGS
I. Introduction On March 16, 2018, the Centers for Medicare and Medicaid Services (CMS) finalized a National Coverage Determination (NCD) that...
EU IVD Regulation – What does it mean for companion diagnostics and LDTs?
Dave Smart, PhD, Director at Diaceutics, discusses the introduction of the EU IVD Regulation. While it is considered a necessary step, the...
View all expert insights

Competitive Benchmarking Reports

Pharma Precision Medicine Readiness Report 2019
PM Readiness Report 2018 Summary
View all reports

Publications

TRK fusion positive cancers: From first clinical data of a TRK inhibitor to future directions
Genetic alterations of neurotrophic tropomyosin or tyrosine receptor kinase (NTRK) 1/2/3 genes generate TRK fusion proteins have been reported in a variety of adult and child cancers from diverse cell/tissue lineages. Larotrectinib, a...
Challenges in the clinical implementation of precision medicine companion diagnostics
The pace of biomarker discovery has increased exponentially over the last few years,ushering in an era of precision medicine (PM) with a growing arsenal of treatments tailored to specific patient populations....
View all publications